Navigation Links
Reportlinker Adds Global Nanobiotechnology Industry
Date:3/21/2011

NEW YORK, March 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Nanobiotechnology Industry

http://www.reportlinker.com/p0181059/Global-Nanobiotechnology-Industry.html

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following technology segments - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 117 companies including many key and niche players worldwide such as Aduro BioTech, Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Unidym, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Celgene Corporation, Abraxis Bioscience, Inc., Elan Pharmaceuticals, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, BioTrove, Inc., NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, Unidym, Inc., and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

1. Nanomaterials 4

Solid Inorganic Nanoparticles 4

Nanocomposites 4

Nanostructured Materials and Membranes 4

Nanotubes and Fullerenes 4

Other Nanomaterials 4

Nanoshells 4

Nanohorns 5

Nanocapsules 5

2. Nanodevices/Tools 5

2. INDUSTRY OVERVIEW 6

A Curtain Raiser 6

Nanobiotechnology - The Next Big Thing 7

Nanotechnology & Biology Tie the Knot: "Two to Tango" 9

Where Conventional Molecular Science Falls Short Nanobio

Steps In 9

What's The Obsession With Size? 9

Why Analysis at the Cellular Level is Important? 10

Lessons from Nature 10

Dawn Breaks On Nanobiotechnology 11

Table 1: Nanobiotechnology and Related Medical Applications

Market (2007): Percentage Share Breakdown of Activity

Distribution by Region and Organizational Set-Up (includes

corresponding Graph/Chart) 11

Table 2: Percentage Breakdown of Number of Nanotechnology

Companies in Healthcare Industry Worldwide by Region/Country

(2008) (includes corresponding Graph/Chart) 12

Table 3: Percentage Breakdown of Number of Nanotechnology

Companies in Healthcare Industry Worldwide by Type - Private

and Public Sector (2008) 12

Table 4: Percentage Breakdown of Number of Nanotechnology

Companies in Healthcare Industry Worldwide By Sector -

Therapeutics and Drug Delivery; Clinical Diagnostics; Drug

Discovery Tools and Biomedical Research; and Biomaterials and

Biomedical Implants (2008) (includes corresponding

Graph/Chart) 12

Table 5: Percentage Breakdown of Number of Nanotechnology

Companies in The field of Therapeutics and Drug Delivery

Worldwide by Area - Targeted Nanoparticles, Solubility &

Reformulation, Sustained Release, Blood Brain Barrier,

Nanomaterial Therapeutics and Others (2008) (includes

corresponding Graph/Chart) 13

Table 6: Percentage Breakdown of Number of Nanotechnology

Companies in the field Therapeutics Worldwide by Therapeutic

Area - Oncology, Infectious Diseases, Central Nervous System

Diseases, Nutraceuticals, Ophthalmology and Others (2008)

(includes corresponding Graph/Chart) 13

Table 7: Percentage Breakdown of Number of Nanotechnology

Companies in the field of Clinical Imaging and Diagnostics

Worldwide by Area - Tags and Probes; Imaging Agents;

Biosensors and Bio-detection; and Instruments (2008)

(includes corresponding Graph/Chart) 13

Demystifying the Intriguing World of Nanobiotech 13

A Meeting Place of Medicine's Best Solutions 14

Nanobiotechnology Promises to Deliver Nanomedicine 16

Nanobiotechnology to Become Viable for All Drug Development

Stages 16

Nanobioproducts in R&D As of 2007 & 2008 17

List of Marketed Nanoparticle-Based Pharmaceutical Products

As of the Year 2007 18

Nanoparticles: The Foundation of Nanobiotechnology 18

Improved Optical Properties and Stability of Nanoparticles 19

Nanoemulsions 19

Diagnosis & Treatment of Cancer 20

The Promise of Nanobiotechnology 20

Biological Weaponries Against Diseases Come in Small Packages 20

Proffered Benefits of Nanobiotechnology 21

Opportunity & Beyond 22

Nanobiotechnology - Will it Live Up to the Expectations? 22

The Future of Nanobiotechnology: Shape of Things to Come 23

Nanobiotechnology: The Outer Limits 23

Futuristics: A Rumination 24

Nanobiotechnology In the Year 2015 24

Field of Nanodiagnostics 24

Field of Regenerative Medicine 24

Field of Targeted Drug Delivery 25

Conclusions 25

3. MARKET DYNAMICS 26

Nanotechnology in the Recent Economic Climate: A Review 26

Nanobio Feels the Pinch or Does It ?: A Closer Look 26

Outlook 27

Developing Countries to Rise Over the Horizon 27

Table 8: Global Nanobiotechnology Market (2007): Percentage

Share Breakdown of Investments by Region (includes

corresponding Graph/Chart) 28

Table 9: Worldwide Funding in Nanotechnology (2004 & 2009):

Percentage Breakdown of Value Investments by Country/Region:

A Comparison (includes corresponding Graph/Chart) 28

Nanomaterials & Nanoparticles Witness Robust Activity 28

Focus on Improved Performance to Bring New Manufacturing

Methods for Nanomaterials 29

Private & Public Companies to Step Up Funding on Nanotechnology 29

Table 10: Worldwide Government Funding in Nanotechnology

(2008-2015) (In US$ Billion) (includes corresponding

Graph/Chart) 30

Increasing Awareness on Technology to Drive Growth 30

Demand for Novel Products to Push Up Growth 30

Nano-Enabled Drug Discovery Holds Tremendous Potential 31

Consolidation Sharpens the Industry's Edge 31

The Regulatory Framework Evolves with the Technology 31

Quantum Dot Patents Pose Legal Tangles 31

Miniaturized Liquid Handling Becomes Progressive 32

Trends in Nanotechnology Enabled Drug Delivery Systems 32

Robust Growth On Cards 32

Table 11: Global Nanotechnology-Enabled Drug Delivery

Systems Market (2015 (P)): Percentage Share Breakdown of

Nanoparticles, Dendrimers, Polymer Therapeutics and Other

Nanostructures (includes corresponding Graph/Chart) 33

Patent Expiries: A Key Driver 33

Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs 34

4. INDUSTRY CHALLENGES & ISSUES 35

Challenges 35

Commercial Exploration: A Treacherous Voyage 36

Conventional Medicine to Contest Nanomedicine Adoption 36

Nanomaterials Use: Weighed Down with Toxicity Concerns 37

Production Issues Continue to Plague Nanobiotech Industry 38

Lack of De Facto Standards: A Challenge to Reckon With 38

Embroilment Over Ethical Issues 39

Social Relevance 40

Economic Relevance 41

5. INDUSTRY STRUCTURE 42

Industry Structure: A Quick Primer 42

A Dissection of Select Segments 42

Nanoparticles 42

Nanotubes and Fullerenes 43

Dendrimers 43

A Peek Into the Regulatory Framework 43

United States 44

Europe 44

A Closer Look at Regional Nano Efforts 44

United States: Unraveling the Country's Edge 44

Table 12: Global Intellectual Property Rights in

Nanotechnology by Leading Countries (2007) 45

Europe: Hot On the Heels of the US 45

Germany 46

France 46

United Kingdom 46

Scandinavia 46

Japan: A Noteworthy Region 47

6. NANOBIO'S EPOCHAL STRIDES IN MODERN MEDICINE 48

A Primer 48

Impact on Drug Delivery Systems 48

Benefits Offered 50

Drug Encapsulation 50

High Level of Specificity 50

Increase in Drug Solubility and Uptake 50

Greater Usage Flexibility 51

Impact On Molecular Diagnostic Imaging 51

Seeing The Unseen 51

Impact On Pharmaceutical Drug Formulations 52

Impact On Therapeutics 53

Silver Nanoparticles as Effective Antimicrobial Agents 53

Modern Day Nanomedicine: A Current Scenario 54

Nanomedicine: The Cynosure of All Eyes 54

Drug Delivery Systems Epitomized by Nanomedicine 55

Targeted NanoDrug Delivery & Release 55

Active and Passive Targeting Mechanisms in Drug Delivery 56

Sustained and Pulsatile Release Mechanisms in Drug Delivery 56

A Peek Into Potential Nanobio Enabled Drug Carriers 56

Micelles 57

Liposomes 57

Dendrimers & Liquid Crystals 57

Nanoparticles 57

Polymeric Nanoparticles 58

Hydrogels 58

Molecularly Imprinted Polymers 58

Microelectromechanical Systems (MEMS) 58

Nanosuspensions 59

Fullerenes: A Platform for GenX Drug Delivery 59

Types of Nano-Based Drug Delivery Systems, Related

Materials, and Structures 60

Dynamics of Regenerative Medicine 60

Tissue Engineering and Restorations 61

Nanotechnology Enabled Diagnostics 62

Promised Path Breaking Applications in Molecular Diagnostics

& Imaging 62

In-Vitro Diagnostics 63

Nanoprobes & Implantable Devices in In-vivo Imaging 64

Nanocomposites in Molecular Labeling & Diagnostics 65

Laboratory-on-a-Chip - A Revolutionary Technology in

Biomolecular Detection 65

Biosensors - Heralding New Opportunities in Molecular

Diagnostics 66

Nanobiosensors - A New Approach to Diagnostics Testing 66

Despite Huge Potential Key Hurdles Remain in

Commercialization 67

Magnetic Nanoparticles for Imaging Applications in MRI 67

Dendrimers Promise Milestone Applications in MRI 67

Conclusions 68

Gauging the Real World Impact of Nanobiotech On Cancer: A Case

Study 68

Quantum Dots Cock a Snook at Traditional Anti-Body Labeling

Agents 69

Chemotherapeutic Reengineering & Gene Therapy: New Treatment

Regimes 69

Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis 70

7. CONCEPTUAL OVERVIEW 71

Nanotechnology: An Introduction 71

A Revolution in the Making 71

Nanobiotechnology: An Exposition 72

Nanobiotechnology & Medicine 72

Nanobiotechnology & Biofuels 73

Global Nanobiotechnology Market (2005): Major Products 73

Global Nanobiotechnology Market (2005): Major Products Under

Development 74

Analysis of Major Technology Segments 74

Nanomaterials 74

Nanoparticles 75

Nanoparticles in Labeling or Bio Tagging 75

Nanoparticles as Biomarkers 76

Classification of Nanoparticles 76

Solid Nanoparticles 76

Solid Lipid Nanoparticles 76

Calcium Phosphate Nanoparticles 76

Dendrimers 77

Nanocomposites 77

Lamellar Nanocomposites 78

Nanostructured Materials and Membranes 78

Nanotubes and Fullerenes 78

Other Nanomaterials 79

Nanoshells 79

Nanohorns 79

Nanocapsules 79

Nanodevices 80

Nanotools 80

Select Nanotools 80

Atomic Force Microscopes 80

Hot Embossing Lithography 81

Dip-Pen Nanolithography 81

8. GLOBAL RESEARCH CENTERS AND INSTITUTIONS 82

Centre for Biologic Nanotechnology (USA) 82

Centre for Biological and Environmental Nanotechnology (USA) 82

Institute of Bioengineering and Nanotechnology (Singapore) 82

The Nanobiotechnology Center (USA) 83

The Tyndall National Institute (Ireland) 83

9. RECENT INDUSTRY ACTIVITY/PRODUCT LAUNCHES 84

IDEX Inks Deal to Acquire Microfluidics 84

NanoMech Takes Over Canano 84

Arrowhead Sells Unidym to Wisepower 84

MP Biomedicals Signs Agreement of Cooperation with Russian

Nanotechnology Corporation 85

Bruker Acquires AFM and OIM Segments from Veeco 85

Audax Inks an Agreement with Brown to Acquire Osteobiologic

Nanotechnology 85

Celgene Acquires Abraxis 86

ELITech Completes Assets Acquisition of Nanogen 86

Life Technologies Acquires BioTrove 86

GSK Inks License With NanoBio to Market NB-001 87

CPN Establishes New Medical Nanobiotechnology R&D Center 87

IBM to Setup New Research Center in Wroclaw 87

Life Technologies and Zymera Ink Licensing Deal for Quantum

Dots Technology 87

APR Acquires Nanotechnology Platform Technology for Preparing

Biotechnology Products 88

Lockheed Teams Up with IIT-Delhi for Nanobiotechnology Research 88

Piedmont Triad to Institute Statewide Nanobiotech Center 88

Biocon and Abraxis Introduce ABRAXANE in India 89

Starpharma Launches a Research Reagent Kit 89

Monash Enters Into a Deal with National Fabrication Facility

of Australia 90

Taiwan Inks Nanotechnology Collaboration Deal with Australia 90

Avanti Institutes New Targeted Drug Delivery Company, Chikujee

Therapeutics 90

CytoViva Rolls Out New Research Tool for Nanotechnology 91

Dabur Obtains DCGI Approval for Nanoxel in New Indications 91

Researchers Discover New Nanoparticles for Treating Brain

Infection 91

Capsulution Tests Nanoparticle-Based Drug Formulation for

Improved Bio-Availability 92

Invitrogen Signs Agreement with Genisphere 92

Sigma-Aldrich Signs Deal With Nanoco Technologies 93

Unidym Sells First License Option for Patent Portfolio to MDA 93

Unidym Spins Off Carbon Nanotubes Therapeutics Business into

Ensysce Biosciences 93

Nacalai USA and Nano-C Enter into Collaboration Agreement for

HPLC Technology 94

Advanced Materials Technology Obtains License for LBL®

Technology from Capsulution 94

Nanogen and The Elitech Group Announce Merger 94

NanoViricides Signs MCRADA Agreement with CDC for Rabies 95

Manhattan Scientifics Acquires Metallicum 95

HemCon Medical Technologies Acquires Alltracel Pharmaceuticals 95

CN Probes Inks Agreement With a Leading MEMS Foundry 96

PrimeGen Biotech LLC Enters into Corporate Alliance with Unidym 96

Ondine Acquires Exclusive License from UCL Business 96

Dabur Introduces Nanotechnology Based Anti-Cancer Drug

Delivery System - Nanoxel 96

Mitsui Ties Up With NIOSH to Evaluate Safety of Carbon Nanotubes 97

Unidym Merges with Carbon Nanotechnologies 97

10. FOCUS ON SELECT GLOBAL PLAYERS 98

Aduro BioTech (USA) 98

Arrowhead Research Corporation (USA) 98

Calando Pharmaceuticals, Inc. (USA) 98

Agilent Technologies Inc (USA) 99

Asklepios BioPharmaceutical Inc (USA) 99

Biosante Phosphate Pharmaceuticals, Inc. (USA) 99

Celgene Corporation (USA) 99

Abraxis Bioscience, Inc (USA) 100

Elan Pharmaceuticals, Inc. (USA) 100

Flamel Technologies, Inc. (France) 100

Gilead Sciences Inc (USA) 101

Life Technologies Corporation (USA) 101

BioTrove, Inc. (USA) 101

NanoBio Corporation (USA) 101

Nanogen, Inc. (US) 102

Nanophase Technologies Corporation (USA) 102

pSivida Ltd (Australia) 103

Sigma Aldrich Company (USA) 103

Starpharma Holdings Ltd. (Australia) 103

Dendritic Nanotechnologies, Inc. (USA) 104

SkyePharma Pharmaceuticals (UK) 104

Unidym, Inc. (USA) 105

Zyvex Instruments LLC (USA) 105

11. GLOBAL MARKET PERSPECTIVE 106

Table 13: World Recent Past, Current & Future Analysis for

Nanobiotechnology by Geographic Region - USA, Japan, Europe,

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 106

Table 14: World Historic Review for Nanobiotechnology by

Geographic Region - USA, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 107

Table 15: World 13-Year Perspective for Nanobiotechnology by

Geographic Region - Percentage Breakdown of Revenues for USA,

Japan, Europe, and Rest of World for Years 2003, 2009 & 2015

(includes corresponding Graph/Chart) 108

Analytics by Product Segment 109

Table 16: World Recent Past, Current & Future Analysis for

Nanomaterials by Geographic Region - USA, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 109

Table 17: World Historic Review for Nanomaterials by

Geographic Region - USA, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 110

Table 18: World 13-Year Perspective for Nanomaterials by

Geographic Region - Percentage Breakdown of Revenues for USA,

Japan, Europe, and Rest of World for Years 2003, 2009 & 2015

(includes corresponding Graph/Chart) 111

Table 19: World Recent Past, Current & Future Analysis for

Solid Inorganic Nanoparticles by Geographic Region - USA,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) 112

Table 20: World Historic Review for Solid Inorganic

Nanoparticles by Geographic Region - USA, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2001 through 2006

(includes corresponding Graph/Chart) 113

Table 21: World 13-Year Perspective for Solid Inorganic

Nanoparticles by Geographic Region - Percentage Breakdown of

Revenues for USA, Japan, Europe, and Rest of World for Years

2003, 2009 & 2015 (includes corresponding Graph/Chart) 114

Table 22: World Recent Past, Current & Future Analysis for

Nanocomposites by Geographic Region - USA, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 115

Table 23: World Historic Review for Nanocomposites by

Geographic Region - USA, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 116

Table 24: World 13-Year Perspective for Nanocomposites by

Geographic Region - Percentage Breakdown of Revenues for USA,

Japan, Europe, and Rest of World for Years 2003, 2009 & 2015

(includes corresponding Graph/Chart) 117

Table 25: World Recent Past, Current & Future Analysis for

Nanostructured Materials & Membranes by Geographic Region -

USA, Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) 118

Table 26: World Historic Review for Nanostructured Materials &

Membranes by Geographic Region - USA, Japan, Europe, and Rest

of World Markets Independently Analyzed with Annual Revenue

Figures in US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 119

Table 27: World 13-Year Perspective for Nanostructured

Materials & Membranes by Geographic Region - Percentage

Breakdown of Revenues for USA, Japan, Europe, and Rest of

World for Years 2003, 2009 & 2015 (includes corresponding

Graph/Chart) 120

Table 28: World Recent Past, Current & Future Analysis for

Nanotubes and Fullerenes by Geographic Region - USA, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2007 through

2015 (includes corresponding Graph/Chart) 121

Table 29: World Historic Review for Nanotubes and Fullerenes

by Geographic Region - USA, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 122

Table 30: World 13-Year Perspective for Nanotubes and

Fullerenes by Geographic Region - Percentage Breakdown of

Revenues for USA, Japan, Europe, and Rest of World for Years

2003, 2009 & 2015 (includes corresponding Graph/Chart) 123

Table 31: World Recent Past, Current & Future Analysis for

Other Nanomaterials by Geographic Region - USA, Japan, Europe,

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 124

Table 32: World Historic Review for Other Nanomaterials by

Geographic Region - USA, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 125

Table 33: World 13-Year Perspective for Other Nanomaterials by

Geographic Region - Percentage Breakdown of Revenues for USA,

Japan, Europe, and Rest of World for Years 2003, 2009 & 2015

(includes corresponding Graph/Chart) 126

Table 34: World Recent Past, Current & Future Analysis for

Nanodevices/Tools by Geographic Region - USA, Japan, Europe,

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 127

Table 35: World Historic Review for Nanodevices/Tools by

Geographic Region - USA, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 128

Table 36: World 13-Year Perspective for Nanodevices/Tools by

Geographic Region - Percentage Breakdown of Revenues for USA,

Japan, Europe, and Rest of World for Years 2003, 2009 & 2015

(includes corresponding Graph/Chart) 129

Analytics by Application 130

Table 37: World Recent Past, Current & Future Analysis for

Nanobiotechnology by Application - Pharmaceuticals, Medical

Devices, Medical Research and Others Independently Analyzed

with Annual Revenue Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 130

Table 38: World 9-Year Perspective for Nanobiotechnology by

Application - Percentage Breakdown of Revenues for

Pharmaceuticals, Medical Devices, Medical Research and Others

for Years 2007, 2009 & 2015 (includes corresponding

Graph/Chart) 131

12. THE UNITED STATES 132

A.Market Analysis 132

Outlook 132

Industry Overview 132

Public Sector Funding 132

Major Nanobiotechnology Institutions and Centers 133

The Nanobiotechnology Center (NBTC) 133

Key technological advances achieved by NBTC in recent years - 133

Principal NBTC Partners 133

Centre for Biologic Nanotechnology (CBN) 134

Centre for Biological and Environmental Nanotechnology (CBEN) 134

Regulatory Environment 135

B.Market Analytics 136

Table 39: US Recent Past, Current & Future Analysis for

Nanobiotechnology by Technology Segment - Nanomaterials

(Solid Inorganic Nanoparticles, Nanocomposites,

Nanostructured Materials & Membranes, Nanotubes and

Fullerenes, Other Nanomaterials) and Nanodevices/ Tools

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 136

Table 40: US Historic Review for Nanobiotechnology by

Technology Segment - Nanomaterials (Solid Inorganic

Nanoparticles, Nanocomposites, Nanostructured Materials &

Membranes, Nanotubes and Fullerenes, Other Nanomaterials)

and Nanodevices/ Tools Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) 137

Table 41: US 13-Year Perspective for Nanobiotechnology by

Technology Segment -Percentage Breakdown of Revenues for

Nanomaterials (Solid Inorganic Nanoparticles,

Nanocomposites, Nanostructured Materials & Membranes,

Nanotubes and Fullerenes, Other Nanomaterials) and

Nanodevices/Tools for Years 2003, 2009 & 2015 (includes

corresponding Graph/Chart) 138

13. JAPAN 139

A.Market Analysis 139

Public Sector Funding 139

B.Market Analytics 140

Table 42: Japanese Recent Past, Current & Future Analysis

for Nanobiotechnology by Technology Segment - Nanomaterials

(Solid Inorganic Nanoparticles, Nanocomposites,

Nanostructured Materials & Membranes, Nanotubes and

Fullerenes, Other Nanomaterials) and Nanodevices/Tools

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 140

Table 43: Japanese Historic Review for Nanobiotechnology by

Technology Segment - Nanomaterials (Solid Inorganic

Nanoparticles, Nanocomposites, Nanostructured Materials &

Membranes, Nanotubes and Fullerenes, Other Nanomaterials)

and Nanodevices/ Tools Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) 141

Table 44: Japanese 13-Year Perspective for Nanobiotechnology

by Technology Segment - Percentage Breakdown of Revenues for

Nanomaterials (Solid Inorganic Nanoparticles,

Nanocomposites, Nanostructured Materials & Membranes,

Nanotubes and Fullerenes, Other Nanomaterials) and

Nanodevices/Tools for Years 2003, 2009 & 2015 (includes

corresponding Graph/Chart) 142

14. EUROPE 143

A.Market Analysis 143

Outlook 143

Market Overview 143

European Union Banks Heavily on Nanobiotechnology 143

Nano2Life Network 144

Major Nanobiotechnology Networks in Europe as of the Year

2006 145

Public Sector Funding 145

Regulatory Environment 145

Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks 146

Focus on Select Markets 146

Germany 146

France 146

United Kingdom 147

Russia 147

Russian Biotech Players Eye Partnerships with Indian

Counterparts 148

Rest of Europe 149

Ireland 149

Market Overview 149

Key Research Institutions/Centers in Nanobiotechnology 149

The Tyndall National Institute 149

The Centre for Research on Adaptive Nanostructures and

NanoDevices 150

The National Centre for Sensor Research 150

The Sami Nasr Institute for Advanced Materials Science 150

B.Market Analytics 151

Table 45: European Recent Past, Current & Future Analysis

for Nanobiotechnology by Technology Segment - Nanomaterials

(Solid Inorganic Nanoparticles, Nanocomposites,

Nanostructured Materials & Membranes, Nanotubes and

Fullerenes, Other Nanomaterials) and Nanodevices/Tools

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 151

Table 46: European Historic Review for Nanobiotechnology by

Technology Segment - Nanomaterials (Solid Inorganic

Nanoparticles, Nanocomposites, Nanostructured Materials &

Membranes, Nanotubes and Fullerenes, Other Nanomaterials)

and Nanodevices/ Tools Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) 152

Table 47: European 13-Year Perspective for Nanobiotechnology

by Technology Segment - Percentage Breakdown of Revenues for

Nanomaterials (Solid Inorganic Nanoparticles,

Nanocomposites, Nanostructured Materials & Membranes,

Nanotubes and Fullerenes, Other Nanomaterials) and

Nanodevices/Tools for Years 2003 2009 & 2015 (includes

corresponding Graph/Chart) 153

15. REST OF WORLD 154

A.Market Analysis 154

Outlook 154

Public Sector Funding 154

Focus on Select Markets 154

Australia 154

Market Overview 154

Major Institutions 155

Commonwealth Scientific and Industrial Research

Organisation (CSIRO) 155

India 155

Market Overview 155

Government Takes Big Initiatives to Promote

Nanobiotechnology 156

Agriculture, Livestock Sectors to Warm Up to

Nanobiotechnology Benefits 156

Korea 156

Taiwan 157

Nanotechnology in Medicine - Small Yet Growing Segment in

Taiwan 158

Iran 158

B.Market Analytics 159

Table 48: Rest of World Recent Past, Current & Future

Analysis for Nanobiotechnology by Technology Segment -

Nanomaterials (Solid Inorganic Nanoparticles,

Nanocomposites, Nanostructured Materials & Membranes,

Nanotubes and Fullerenes, Other Nanomaterials) and

Nanodevices/Tools Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 159

Table 49: Rest of World Historic Review for

Nanobiotechnology by Technology Segment - Nanomaterials

(Solid Inorganic Nanoparticles, Nanocomposites,

Nanostructured Materials & Membranes, Nanotubes and

Fullerenes, Other Nanomaterials) and Nanodevices/ Tools

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) 160

Table 50: Rest of World 13-Year Perspective for

Nanobiotechnology by Technology Segment - Percentage

Breakdown of Revenues for Nanomaterials (Solid Inorganic

Nanoparticles, Nanocomposites, Nanostructured Materials &

Membranes, Nanotubes and Fullerenes, Other Nanomaterials)

and Nanodevices/Tools for Years 2003, 2009 & 2015 (includes

corresponding Graph/Chart) 161

COMPETITIVE LANDSCAPE

Total Companies Profiled: 117 (including Divisions/Subsidiaries - 122)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 75

Canada 2

Japan 1

Europe 32

France 3

Germany 8

The United Kingdom 9

Rest of Europe 12

Asia-Pacific (Excluding Japan) 9

Middle-East 3

------------------------------------------

To order this report:

: Global Nanobiotechnology Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Global Biochips Industry
2. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
3. Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, Whats Hot and Whats Not , The
4. Reportlinker Adds Three Alternative Scenarios of the Future In Vitro Diagnostics Market through 2018
5. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan; Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
6. Reportlinker Adds The 2011 Top Ten Worlds Leading Life Science Intermediates Companies
7. Reportlinker Adds Biomarkers - Technologies, Markets and Companies
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. Reportlinker Adds RNAi - Technologies, Markets and Companies
10. Reportlinker Adds Future Outlook for Common IT Platforms - Radiology and Cardiology
11. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Germany and ... -- QGEN ; Frankfurt Prime Standard: QIA) ... QIAseq Targeted RNA Panels for gene expression profiling, expanding ... sequencing (NGS). The panels enable researchers to select from ... fold changes and discover interactions between genes, cellular phenotypes ...
(Date:2/11/2016)... Feb. 11, 2016  Wellcentive today announced it ... Portland, Oregon -based community care organization (CCO) ... health analytics, quality reporting and care management solutions ... its team of quality managers, analysts and care ... provider groups serving FamilyCare members. ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem Cells Group, ... Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection and other biological ... Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, ...
Breaking Biology Technology:
(Date:2/11/2016)... -- Vigilant Solutions announces today that its license plate recognition (LPR) ... Lee,s Summit Police Department to improve safety ... a homicide suspect. Kansas City , ... miles and is home to roughly 100,000 residents. ... license plate reader system and also leverages Vigilant,s network of ...
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ... "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ... report to their offering. --> ... has announced the addition of the ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
Breaking Biology News(10 mins):